

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Review of Novel Therapeutics in Cardiac Arrest (ReNTICA) - Systematic Review Protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-053304
Article Type:	Protocol
Date Submitted by the Author:	11-May-2021
Complete List of Authors:	Murphy, Travis; University of Florida, Department of Emergency Medicine McCall-Wright, Patti; University of Florida Clinical and Translational Science Institute (CTSI) Aleong, Elizabeth; University of Florida Taylor, Noelle; University of Florida Messina, Maiya-Mari; University of Florida Carrazana, Gabriela; University of Florida Maciel, Carolina; University of Florida Health, Neurology and Neurosurgery Becker, Torben; University of Florida Health, Emergency Medicine Chowdhury, Muhammad Abdul Baker ; University of Florida Health, Emergency Medicine Snipes, Garrett; University of Florida College of Medicine
Keywords:	CLINICAL PHARMACOLOGY, Adult intensive & critical care < INTENSIVE & CRITICAL CARE, Neurological injury < NEUROLOGY, THERAPEUTICS, Adult cardiology < CARDIOLOGY, ACCIDENT & EMERGENCY MEDICINE

SCHOLARONE™
Manuscripts

Review of Novel Therapeutics in Cardiac Arrest (ReNTICA) - Systematic Review Protocol

Travis W. Murphy¹, Garrett Snipes^{1,2}, Muhammad Abdul Baker Chowdhury¹, Patti McCall-Wright³, Elizabeth Aleong⁴, Noelle Taylor⁴, Maiya-Mari Messina⁴, Gabriela Carrazana⁴, Carolina B. Maciel⁵, Torben K. Becker¹

1 University of Florida Department of Emergency Medicine

2 University of Florida Department of Internal Medicine

3 University of Florida Clinical Translational Science Institute

4 University of Florida

5 University of Florida Departments of Neurology and Neurosurgery

Corresponding Author:

Travis W Murphy, MD

1329 SW 16th St Ste 5270

Gainesville, FL 32608

twmurphy@ufl.edu

Word Count: 1907/4000

I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in BMJ Open and any other BMJ products and to exploit all rights, as set out in our [licence](#).

Travis W Murphy, MD

Abstract

Introduction

Cardiac arrest remains a common and devastating cause of death and disability worldwide. While targeted temperature management has become standard of care to improve functional neurologic outcome, few pharmacologic interventions have shown similar promise.

Methods/analysis

This systematic review will focus on prospective human studies from 2015 to 2020 with a primary focus on impact on functional neurologic outcome. Prospective studies that include pharmacologic agents given during or after cardiac arrest will be included. Study selection will be in keeping with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. If sufficient data involving a given agent are available, a meta-analysis will be conducted and compared to current evidence for therapies recommended in international practice guidelines.

Ethics and dissemination

Formal ethical approval will not be required as primary data will not be collected. The results will be disseminated through peer-reviewed publication, conference presentation and lay press.

Prospero registration number: International Prospective Register for Systematic Reviews (PROSPERO) number CRD42021230216

Article Summary

Strengths and limitations of this study

- Systematic review and meta-analysis of prospective trials investigating therapeutic agents in cardiac arrest.
- Inclusion of outcome measurements to quantify the effect of proposed therapeutic interventions on neurologic function after cardiac arrest.
- Limitation in the number of studies investigating a given therapy may diminish observed effects.
- Potential identification of therapies with positive impact on functional outcome following cardiac arrest.
- Key words: cardiac arrest, heart arrest, pharmacologic agents, functional neurologic outcome

Introduction

Cardiac arrest remains a common and often devastating cause of death and disability worldwide.[1] Outcomes are contingent on the severity of overall hypoxic-ischemic brain injury burden, which comprises primary injury during circulation standstill and ongoing secondary brain injury that occurs in the aftermath of resuscitation. Besides targeted temperature management, therapeutic options targeting improvement in neurologic outcome are scarce.[2] International practice guidelines currently recommend epinephrine/adrenaline, amiodarone and lidocaine/lignocaine.[3–5] While there is good evidence for improved survival with these medications, there is little evidence for a positive impact of these medications on functional neurologic outcomes specifically[3,5,6]. Functional neurologic outcome is less commonly the primary focus of cardiac arrest research but arguably a more granular patient-centered variable rather than rate of return of spontaneous circulation or survival. Unlike targeted temperature management, few advances have been made in pharmacologic approaches to improve functionally intact neurologic survival following cardiac arrest.[2,5,7,8] Several novel compounds have been investigated in animal studies, with some notation of effect on neurologic function, though only a small minority have made the transition from animal models into human trials.[7] The review proposed here will focus on identifying the best available data from human studies.

A similar review of the literature was performed in 2015, though this was focused on cataloging the therapies utilized and did not focus on studies that included functional outcome measurements.[8] Another recent systematic review reported the rate of translation from animal models to human trials for therapies targeted at cardiac arrest.[7] Though again, this review did not have a specific focus on functional neurologic outcome. While the review published by Lind et al. identified the large number of experimental therapies targeted at post-cardiac arrest physiology, the authors noted a relative dearth of clinical trials investigating those same therapies in humans.[7] Additionally, the review published in 2021 did not compare the effects of different pharmacologic agents.[7] The review proposed here seeks to compile the best available evidence for pharmacologic interventions that will improve functional neurologic outcomes in humans following cardiac arrest and compare this directly to current practice guidelines.

Objectives

The objective of our study is to systematically review the literature for prospective studies that evaluated the performance of pharmacologic agents used in adult cardiac arrest compared to standard resuscitation treatments currently advocated in practice guidelines. This will include studies regardless of initial cardiac rhythm and independent of the use of targeted temperature management.

Methods and Design

Population

The systematic review will focus on studies that include patients aged >15 years who have been resuscitated from cardiac arrest but are not conscious upon return of spontaneous circulation with arms for both intervention and control.

Interventions

The interventions to be evaluated include any pharmacologic agent given during cardiac arrest itself or in the immediate post-arrest period (defined as the initial 24 hours).

Comparisons

The interventions identified will be compared to current international practice guidelines and the pharmacologic agents advocated there (epinephrine/adrenaline, amiodarone, and lidocaine/lignocaine).

Outcome

The primary outcomes required of included studies will be survival and neurologic function as defined by one of the following neurologic scales: Cerebral Performance Category, modified Rankin Scale, Glasgow Outcome Scale/Glasgow Outcome Scale-Extended.

Study Design

The systematic review and meta-analysis will include prospective therapeutic studies investigating the use of a pharmacologic agent during or after cardiac arrest with a primary focus on effects on neurologic outcome. This will include systematic reviews, meta-analyses, randomized control trials, adaptive clinical trials, prospective cohort and observational studies, and non-randomized clinical trials. Studies that compare one intervention to standard ACLS resuscitation as the control will be included. The review will exclude studies without a control group using either placebo or current standard care. Retrospective studies will be excluded including retrospective cohorts, case control studies, cross sectional studies, case reports, and case series. This review has been registered on the International Prospective Register for Systematic Reviews (PROSPERO) number CRD42021230216.

Search Strategy

A three-step process will be used to identify eligible studies, including an initial search, title and abstract screening and full-text manuscript review. A professional systematic review librarian (PMW) will develop search criteria in discussion with the authors to include all relevant studies pertaining to adult, human studies of pharmacologic treatment of cardiac arrest. The databases that will be searched are PubMed, Web of Science and EMBASE from the year 2015 to 2020, inclusive. No language restrictions will be applied. Figure 1 shows an example search algorithm for PubMed. Initial deduplication will be performed using EndNote (Clarivate Analytics, Philadelphia, Pennsylvania, USA).[9]

Study Selection

Literature search results will be uploaded from EndNote and screened through DistillerSR (Evidence Partners, Ottawa, Ontario, Canada). Study titles and abstracts will be screened for relevance in duplicate, blindly and independently, by four reviewers (EA, NT, GC, MM). Eligible studies will then be assessed for quality in secondary screening through review of full-text manuscripts before data abstraction. This process will be reported using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram. The PRISMA-P Checklist pertaining to this protocol is available as Supplement 1. Any conflicting remarks regarding studies will be adjudicated through discussion before inclusion in the final analysis.

Quality Assessment

Each article will undergo initial screening in parallel by two independent reviewers to minimize bias. All selected articles will be reviewed with senior authors during full-text review.

Data Extraction

Quantitative data will be extracted from studies meeting inclusion upon full-text review by a professional biostatistician (MABC). Data extracted will be specifically those pertinent to the systematic review and all others that fit into the synthesis of outcome parameters from all studies and meets the potential for inclusion in a meta-analysis. Data extraction will be independently cross-checked. Data

1
2
3 produced from this systematic review including the statistical code and dataset of articles screened will
4 be published in a data repository.
5

6 **Endpoint**

7 Results of the systematic review will be grouped by drug and drug class. The primary outcomes will be
8 survival and neurologic function as defined by one of the following neurologic scales: Cerebral
9 Performance Category, modified Rankin Scale, Glasgow Outcome Scale/Glasgow Outcome Scale-
10 Extended. Provided they are available in the original studies, secondary outcomes will be ICU length of
11 stay, Ventilator days, rates of sepsis, rates of pneumonia, rate of tracheostomy, rate of acute kidney
12 injury and need for CVVH/HD (in the hospital or afterwards). We will also include secondary outcomes of
13 functional capacity including Barthel Index, Katz Index, Lawton-Brody Instrumental Activities of Daily
14 Living Scale, and rates of discharge to rehab facility if included in the original studies. Any follow-up
15 duration will be accepted as there is considerable variability in the existing literature.
16
17

18 **Patient and Public Involvement**

19 No patients were involved with the planning of this protocol.
20
21

22 **Analysis**

23 **Descriptive Analysis**

24 A narrative synthesis of the final studies included will be developed based on the different
25 pharmacologic agents identified. The impact of each of these agents on the primary and secondary
26 outcome mentioned above will be described in addition to a formal meta-analysis of studies using each
27 pharmacologic agent identified.
28
29
30

31 **Statistical Analysis**

32 The primary focus of this review is to detect evidence for the impact of the pharmacologic agents
33 identified on survival and functional neurologic outcome. As functional outcome is reported with some
34 degree of heterogeneity, we are including three of the most widely reported functional outcome scales
35 and not limiting to one over the others. As functional neurologic outcome is not always explicitly
36 reported using one of these sales, we do anticipate some limitation in the ability to directly compare
37 one agent to another. However, when available, pharmacologic agents will be compared as equitably as
38 possible using all available outcome parameters reported in the index studies. The percentage of
39 patients receiving a given pharmacologic agent with a favorable neurologic outcome according to each
40 specific scale will be reported. Based on the availability of data from primary sources, subgroup analysis
41 within cohorts treated with the same pharmacologic agent will also be performed to identify
42 populations most likely to benefit from a given agent.
43
44
45

46 **Data synthesis**

47 Results will be presented in accordance with the Preferred Reporting Items for Systematic Reviews and
48 Meta-Analysis (PRISMA) statement. A PRISMA flow diagram will be used to summarize study selection.
49 Tabulated data showing relative proportion of patients with favorable functional neurologic outcome for
50 each pharmacologic agent will be presented. We will rank agents by proportion of favorable outcomes.
51 For secondary outcome variables, we will present synthesized data as available in separate tables but
52 will otherwise provide a separate narrative summary of the data available for each agent. We will
53 produce a hierarchy of pharmacologic agents based on the quality of evidence available and degree of
54 effects on outcome variables.
55
56
57
58
59
60

Meta-analysis

A meta-analysis of the pharmacologic agents found to have been studied with a focus on functional neurologic outcome will be performed. The results of this meta-analysis will then be compared to the best available evidence for medications recommended in practice guidelines to provide context and rank relative efficacy.

Confidence in cumulative evidence

Cochrane tools for assessment of study quality will be utilized as appropriate. (ROBINS-1 and RoB 2.0). Two independent authors will assess the risks of bias in studies considered for full-text review. Conflicts will be adjudicated with discussion and involvement of a third author (TM or CM) as necessary.

Discussion

This systematic review and meta-analysis will provide evidence for further study or use of compounds that are most likely to benefit patients following cardiac arrest in terms of functional status. The conclusions will be the result of careful accumulation of the highest-quality evidence available and will compare to current practice guidelines to place the effects in context. With a primary focus on the ability of a given pharmacologic agent to not only provide a survival benefit but protect the neurologic function of patients following cardiac arrest, this review and meta-analysis will be unique in its aim to identify agents with the greatest potential to benefit these patients.

Ethics and dissemination

No ethical or safety considerations were considered based on the nature of this review. Dissemination of findings through a peer-reviewed publication upon the conclusion of the meta-analysis.

Author Contributions

Travis Murphy: Conception and design of work, analysis, drafting of work, final approval *Garrett Snipes*: Conception and design of work, drafting of work *Muhammad Abdul Baker Chowdhury*: Conception and design of work, analysis *Patti McCall-Wright*: Conception and design of work, analysis *Elizabeth Aleong*: Analysis *Noelle Taylor*: Analysis *Maiya Messina*: Analysis *Gabriela Carrazana*: Analysis *Carolina Maciel*: Conception and design of work, analysis *Torben Becker*: Conception and design of work. All authors have reviewed and contributed to this final written manuscript.

Funding statement

This project received funding from the University of Florida Center for Translational Science Institute (Voucher #LSR06-001) to support professional library services.

Competing interests statement

The authors have no competing interests.

References

- [1] Kiguchi T, Okubo M, Nishiyama C, Maconochie I, Ong MEH, Kern KB, et al. Out-of-hospital cardiac arrest across the World: First report from the International Liaison Committee on Resuscitation

- 1
2
3 (ILCOR). *Resuscitation* 2020;152:39–49. <https://doi.org/10.1016/j.resuscitation.2020.02.044>.
- 4
5 [2] Panchal AR, Berg KM, Hirsch KG, Kudenchuk PJ, Del Rios M, Cabanãs JG, et al. 2019 American
6 Heart Association Focused Update on Advanced Cardiovascular Life Support: Use of Advanced
7 Airways, Vasopressors, and Extracorporeal Cardiopulmonary Resuscitation during Cardiac Arrest:
8 An Update to the American Heart Association Guidelines f. *Circulation* 2019;140:E881–94.
9 <https://doi.org/10.1161/CIR.0000000000000732>.
- 10
11 [3] Panchal AR, Berg KM, Kudenchuk PJ, Del Rios M, Hirsch KG, Link MS, et al. 2018 American Heart
12 Association Focused Update on Advanced Cardiovascular Life Support Use of Antiarrhythmic
13 Drugs During and Immediately After Cardiac Arrest: An Update to the American Heart Association
14 Guidelines for Cardiopulmonary Resuscitation and Em. *Circulation* 2018;138:e740–9.
15 <https://doi.org/10.1161/CIR.0000000000000613>.
- 16
17 [4] Holmberg MJ, Issa MS, Moskowitz A, Morley P, Welsford M, Neumar RW, et al. Vasopressors
18 during adult cardiac arrest: A systematic review and meta-analysis. *Resuscitation* 2019.
19 <https://doi.org/10.1016/j.resuscitation.2019.04.008>.
- 20
21 [5] Soar J, MacOnochie I, Wyckoff MH, Olasveengen TM, Singletary EM, Greif R, et al. 2019
22 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care
23 Science with Treatment Recommendations: Summary from the Basic Life Support; Advanced Life
24 Support; Pediatric Life Support; Neonatal Life Support; Education, I. *Circulation* 2019.
25 <https://doi.org/10.1161/CIR.0000000000000734>.
- 26
27 [6] Kudenchuk PJ, Brown SP, Daya M, Rea T, Nichol G, Morrison LJ, et al. Amiodarone, Lidocaine, or
28 Placebo in Out-of-Hospital Cardiac Arrest. *N Engl J Med* 2016;374:1711–22.
29 <https://doi.org/10.1056/nejmoa1514204>.
- 30
31 [7] Lind PC, Johannsen CM, Vammen L, Magnussen A, Andersen LW, Granfeldt A. Translation from
32 animal studies of novel pharmacological therapies to clinical trials in cardiac arrest: A systematic
33 review. *Resuscitation* 2021;158:258–69. <https://doi.org/10.1016/j.resuscitation.2020.10.028>.
- 34
35 [8] Lundin A, Djärv T, Engdahl J, Hollenberg J, Nordberg P, Ravn-Fischer A, et al. Drug therapy in
36 cardiac arrest: A review of the literature. *Eur Hear J - Cardiovasc Pharmacother* 2016;2:54–75.
37 <https://doi.org/10.1093/ehjcvp/pvv047>.
- 38
39 [9] Bramer WM, Giustini D, De Jonge GB, Holland L, Bekhuis T. De-duplication of database search
40 results for systematic reviews in EndNote. *J Med Libr Assoc* 2016;104:240–3.
41 <https://doi.org/10.5195/jmla.2016.24>.
- 42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59

Figure 1. Example Search Algorithm for PubMed

PubMed

Cardiac Arrest

cardiac arrest[MeSH Terms] OR arrest, cardiopulmonary[MeSH Terms] OR heart arrest[MeSH Terms] OR deep hypothermic circulatory arrest[MeSH Terms] OR ventricular fibrillation[MeSH Terms] OR ventricular tachycardia[MeSH Terms] OR asystole[MeSH Terms] OR cardiopulmonary resuscitation[MeSH Terms] OR advanced cardiac life support[MeSH Terms] OR cardiac death[MeSH Terms] OR sudden cardiac death[MeSH Terms] OR cardiac death, sudden[MeSH Terms] OR cardiac arrest[Text Word] OR cardiopulmonary arrest[Text Word] OR heart arrest[Text Word] OR circulatory arrest[Text Word] OR ventricular fibrillation[Text Word] OR ventricular tachycardia[Text Word] OR pulseless electrical activity[Text Word] OR asystole[Text Word] OR cardiovascular arrest[Text Word] OR cardiopulmonary arrest[Text Word] OR cardiopulmonary resuscitation[Text Word] OR defibrillation[Text Word] OR advanced cardiac life support[Text Word] OR ACLS[Text Word] OR cardiac death[Text Word] OR sudden cardiac death[Text Word] OR fatal arrhythmia[Text Word] **2015:2021[pdat]**

Results 1: 57,400

AND

Survival

survival[MeSH Terms] OR mortality[MeSH Terms] OR survival[Text Word] OR mortality[Text Word] **2015:2021[pdat]**

Results 2: 705, 713

AND

Functional Outcome

glasgow outcome scale[MeSH Terms] OR glasgow outcome scale[Text Word] OR modified rankin scale[Text Word] OR cerebral performance categories score[Text Word] OR prognosis[MeSH Terms] OR disability evaluation[MeSH Terms] OR prognosis[Text Word] OR disability evaluation[Text Word] **2015:2021[pdat]**

Results 3: 603,078

AND

Pharmacology

drug*[Text Word] OR drug therapy[Text Word] OR medication[Text Word] OR phamacolog*[Text Word] OR pharmaceutical*[Text Word] OR therap*[Text Word] OR injection[Text Word] OR infusion[Text Word] OR cardiovascular agents[Text Word] OR drug administration schedule[Text Word] OR therapeutics[Text Word] OR intravenous administration[Text Word] OR dose response relationship[Text Word] OR cardiovascular agents[MeSH Terms] OR therapeutics[MeSH Terms] OR drug administration

1
2
3 schedule[MeSH Terms] OR dose response relationship, drug[MeSH Terms] OR vasopressor agents[MeSH
4 Terms] OR epinephrine[MeSH Terms] OR vasopressins[MeSH Terms] OR norepinephrine[MeSH Terms]
5 OR Simendan[MeSH Terms] OR methoxamine[MeSH Terms] OR amiodarone[MeSH Terms] OR sodium
6 channel blockers[MeSH Terms] OR lidocaine[MeSH Terms] OR lignocaine[MeSH Terms] OR
7 procainamide[MeSH Terms] OR flecainide[MeSH Terms] OR mexiletine[MeSH Terms] OR
8 quinidine[MeSH Terms] OR adrenergic beta blockers[MeSH Terms] OR sotalol[MeSH Terms] OR apo
9 labetalol[MeSH Terms] OR metoprolol[MeSH Terms] OR nadolol[MeSH Terms] OR bisoprolol[MeSH
10 Terms] OR carvedilol[MeSH Terms] OR isoproterenol[MeSH Terms] OR calcium channel blockers[MeSH
11 Terms] OR diltiazem[MeSH Terms] OR verapamil[MeSH Terms] OR digoxin[MeSH Terms] OR
12 isoprenaline[MeSH Terms] OR theophylline[MeSH Terms] OR aminophylline[MeSH Terms] OR
13 magnesium[MeSH Terms] OR thrombolytic agents[MeSH Terms] OR thrombolytic drugs[MeSH Terms]
14 OR thrombolytic therapies[MeSH Terms] OR corticosteroids[MeSH Terms] OR sodium
15 bicarbonate[MeSH Terms] OR erythropoietin[MeSH Terms] OR crystalloid solutions[MeSH Terms] OR
16 ascorbic acid[MeSH Terms] OR vitamin e[MeSH Terms] OR vitamin b1[MeSH Terms] OR
17 melatonin[MeSH Terms] OR colloids[MeSH Terms] OR xenon[MeSH Terms] OR argon[MeSH Terms] OR
18 hydrogen[MeSH Terms] OR hydrogen sulfide[MeSH Terms] OR nitric oxide[MeSH Terms] OR carbon
19 monoxide[MeSH Terms] OR anesthetic agents[MeSH Terms] OR anesthetic drugs[MeSH Terms] OR
20 propofol[MeSH Terms] OR ketamine[MeSH Terms] OR vasopressor[Text Word] OR epinephrine[Text
21 Word] OR vasopressin[Text Word] OR norepinephrine[Text Word] OR levosimendan[Text Word] OR
22 simendan[Text Word] OR methoxamine[Text Word] OR amiodarone[Text Word] OR sodium channel
23 blockers[Text Word] OR lidocaine[Text Word] OR lignocaine[Text Word] OR procainamide[Text Word]
24 OR flecainide[Text Word] OR mexiletine[Text Word] OR quinidine[Text Word] OR beta blocker[Text
25 Word] OR sotalol[Text Word] OR labetalol[Text Word] OR metoprolol[Text Word] OR nadolol[Text
26 Word] OR bisoprolol[Text Word] OR carvedilol[Text Word] OR isoproterenol[Text Word] OR calcium
27 channel blocker[Text Word] OR diltiazem[Text Word] OR verapamil[Text Word] OR atropine[Text Word]
28 OR atropine[MeSH Terms] OR digoxin[Text Word] OR isoprenaline[Text Word] OR theophylline[Text
29 Word] OR magnesium[Text Word] OR thrombolytic[Text Word] OR corticosteroids[Text Word] OR
30 sodium bicarbonate[Text Word] OR erythropoietin[Text Word] OR crystalloid[Text Word] OR
31 colloid[Text Word] OR vitamin c[Text Word] OR ascorbic acid[Text Word] OR vitamin e[Text Word] OR
32 vitamin b[Text Word] OR thiamine[Text Word] OR edavarone[Text Word] OR melatonin[Text Word] OR
33 medical gas[Text Word] OR xenon[Text Word] OR argon[Text Word] OR hydrogen[Text Word] OR
34 hydrogen sulfide[Text Word] OR nitric oxide[Text Word] OR carbon monoxide[Text Word] OR
35 anesthetics[Text Word] OR propofol[Text Word] OR ketamine[Text Word] OR adrenergic alpha
36 agonists[MeSH Terms] OR Adrenergic alpha-1 Receptor Antagonists[MeSH Terms] OR adrenergic beta
37 antagonists[MeSH Terms] OR adjuvants, anesthesia[MeSH Terms] OR analgesics[MeSH Terms] OR
38 anesthetics, dissociative[MeSH Terms] OR anesthetics, local[MeSH Terms] OR anti arrhythmia
39 agents[MeSH Terms] OR antihypertensive agents[MeSH Terms] OR antioxidants[MeSH Terms] OR
40 bronchodilator agents[MeSH Terms] OR cardiotoxic agents[MeSH Terms] OR cardiovascular
41 agents[MeSH Terms] OR cytochrome p 450 CYP1A2 inhibitors[MeSH Terms] OR cytochrome p 450
42 CYP2C9 inhibitors[MeSH Terms] OR cytochrome p 450 CYP2D6 inhibitors[MeSH Terms] OR cytochrome p
43 450 CYP3A inhibitors[MeSH Terms] OR enzyme inhibitors[MeSH Terms] OR excitatory amino acid
44 antagonists[MeSH Terms] OR fibrinolytic agents[MeSH Terms] OR muscarinic antagonists[MeSH Terms]
45 OR mydriatics[MeSH Terms] OR parasympatholytics[MeSH Terms] OR phosphodiesterase 3
46 inhibitors[MeSH Terms] OR potassium channel blockers[MeSH Terms] OR purinergic p1 receptor
47
48
49
50
51
52
53
54
55
56
57
58
59

1
2
3 antagonists[MeSH Terms] OR sympathomimetics[MeSH Terms] OR sympatholytics[MeSH Terms] OR
4 vasoconstrictor agents[MeSH Terms] OR vasodilator agents[MeSH Terms] OR vitamins[MeSH Terms] OR
5 Adrenergic alpha-Agonists[Text Word] OR Adrenergic alpha-1 Receptor Antagonists[Text Word] OR
6 Adrenergic beta-Antagonists[Text Word] OR Adjuvants, Anesthesia[Text Word] OR Analgesics[Text
7 Word] OR Anesthetics, Dissociative[Text Word] OR Anesthetics, Local[Text Word] OR Anti-Arrhythmia
8 Agents[Text Word] OR Antihypertensive Agents[Text Word] OR Antioxidants[Text Word] OR
9 Bronchodilator Agents[Text Word] OR Cardiotonic Agents[Text Word] OR Cardiovascular Agents[Text
10 Word] OR Cytochrome P-450 CYP1A2 Inhibitors[Text Word] OR Cytochrome P-450 CYP2C9
11 Inhibitors[Text Word] OR Cytochrome P-450 CYP2D6 Inhibitors[Text Word] OR Cytochrome P-450 CYP3A
12 Inhibitors[Text Word] OR Enzyme Inhibitors[Text Word] OR Excitatory Amino Acid Antagonists[Text
13 Word] OR Fibrinolytic Agents[Text Word] OR Muscarinic Antagonists[Text Word] OR Mydriatics[Text
14 Word] OR Parasympatholytics[Text Word] OR Phosphodiesterase 3 Inhibitors[Text Word] OR Potassium
15 Channel Blockers[Text Word] OR Purinergic P1 Receptor Antagonists[Text Word] OR
16 Sympathomimetics[Text Word] OR Sympatholytics[Text Word] OR Vasoconstrictor agents[Text Word]
17 OR Vasodilator **2015:2021[mdat]**

18
19
20
21
22 Results 4: 2, 723, 077

23
24 Combined Results 1+2+3+4: 4308

25
26 Date: December 7, 2020
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1. Example Search Algorithm for PubMed**PubMed****Cardiac Arrest**

cardiac arrest[MeSH Terms] OR arrest, cardiopulmonary[MeSH Terms] OR heart arrest[MeSH Terms] OR deep hypothermic circulatory arrest[MeSH Terms] OR ventricular fibrillation[MeSH Terms] OR ventricular tachycardia[MeSH Terms] OR asystole[MeSH Terms] OR cardiopulmonary resuscitation[MeSH Terms] OR advanced cardiac life support[MeSH Terms] OR cardiac death[MeSH Terms] OR sudden cardiac death[MeSH Terms] OR cardiac death, sudden[MeSH Terms] OR cardiac arrest[Text Word] OR cardiopulmonary arrest[Text Word] OR heart arrest[Text Word] OR circulatory arrest[Text Word] OR ventricular fibrillation[Text Word] OR ventricular tachycardia[Text Word] OR pulseless electrical activity[Text Word] OR asystole[Text Word] OR cardiovascular arrest[Text Word] OR cardiopulmonary arrest[Text Word] OR cardiopulmonary resuscitation[Text Word] OR defibrillation[Text Word] OR advanced cardiac life support[Text Word] OR ACLS[Text Word] OR cardiac death[Text Word] OR sudden cardiac death[Text Word] OR fatal arrhythmia[Text Word] **2015:2021[pdat]**

Results 1: 57,400

AND

Survival

survival[MeSH Terms] OR mortality[MeSH Terms] OR survival[Text Word] OR mortality[Text Word] **2015:2021[pdat]**

Results 2: 705, 713

AND

Functional Outcome

glasgow outcome scale[MeSH Terms] OR glasgow outcome scale[Text Word] OR modified rankin scale[Text Word] OR cerebral performance categories score[Text Word] OR prognosis[MeSH Terms] OR disability evaluation[MeSH Terms] OR prognosis[Text Word] OR disability evaluation[Text Word] **2015:2021[pdat]**

Results 3: 603,078

AND

Pharmacology

drug*[Text Word] OR drug therapy[Text Word] OR medication[Text Word] OR phamacolog*[Text Word] OR pharmaceutical*[Text Word] OR therap*[Text Word] OR injection[Text Word] OR infusion[Text Word] OR cardiovascular agents[Text Word] OR drug administration schedule[Text Word] OR therapeutics[Text Word] OR intravenous administration[Text Word] OR dose response relationship[Text Word] OR cardiovascular agents[MeSH Terms] OR therapeutics[MeSH Terms] OR drug administration

1
2
3 schedule[MeSH Terms] OR dose response relationship, drug[MeSH Terms] OR vasopressor agents[MeSH
4 Terms] OR epinephrine[MeSH Terms] OR vasopressins[MeSH Terms] OR norepinephrine[MeSH Terms]
5 OR Simendan[MeSH Terms] OR methoxamine[MeSH Terms] OR amiodarone[MeSH Terms] OR sodium
6 channel blockers[MeSH Terms] OR lidocaine[MeSH Terms] OR lignocaine[MeSH Terms] OR
7 procainamide[MeSH Terms] OR flecainide[MeSH Terms] OR mexiletine[MeSH Terms] OR
8 quinidine[MeSH Terms] OR adrenergic beta blockers[MeSH Terms] OR sotalol[MeSH Terms] OR apo
9 labetalol[MeSH Terms] OR metoprolol[MeSH Terms] OR nadolol[MeSH Terms] OR bisoprolol[MeSH
10 Terms] OR carvedilol[MeSH Terms] OR isoproterenol[MeSH Terms] OR calcium channel blockers[MeSH
11 Terms] OR diltiazem[MeSH Terms] OR verapamil[MeSH Terms] OR digoxin[MeSH Terms] OR
12 isoprenaline[MeSH Terms] OR theophylline[MeSH Terms] OR aminophylline[MeSH Terms] OR
13 magnesium[MeSH Terms] OR thrombolytic agents[MeSH Terms] OR thrombolytic drugs[MeSH Terms]
14 OR thrombolytic therapies[MeSH Terms] OR corticosteroids[MeSH Terms] OR sodium
15 bicarbonate[MeSH Terms] OR erythropoietin[MeSH Terms] OR crystalloid solutions[MeSH Terms] OR
16 ascorbic acid[MeSH Terms] OR vitamin e[MeSH Terms] OR vitamin b1[MeSH Terms] OR
17 melatonin[MeSH Terms] OR colloids[MeSH Terms] OR xenon[MeSH Terms] OR argon[MeSH Terms] OR
18 hydrogen[MeSH Terms] OR hydrogen sulfide[MeSH Terms] OR nitric oxide[MeSH Terms] OR carbon
19 monoxide[MeSH Terms] OR anesthetic agents[MeSH Terms] OR anesthetic drugs[MeSH Terms] OR
20 propofol[MeSH Terms] OR ketamine[MeSH Terms] OR vasopressor[Text Word] OR epinephrine[Text
21 Word] OR vasopressin[Text Word] OR norepinephrine[Text Word] OR levosimendan[Text Word] OR
22 simendan[Text Word] OR methoxamine[Text Word] OR amiodarone[Text Word] OR sodium channel
23 blockers[Text Word] OR lidocaine[Text Word] OR lignocaine[Text Word] OR procainamide[Text Word]
24 OR flecainide[Text Word] OR mexiletine[Text Word] OR quinidine[Text Word] OR beta blocker[Text
25 Word] OR sotalol[Text Word] OR labetalol[Text Word] OR metoprolol[Text Word] OR nadolol[Text
26 Word] OR bisoprolol[Text Word] OR carvedilol[Text Word] OR isoproterenol[Text Word] OR calcium
27 channel blocker[Text Word] OR diltiazem[Text Word] OR verapamil[Text Word] OR atropine[Text Word]
28 OR atropine[MeSH Terms] OR digoxin[Text Word] OR isoprenaline[Text Word] OR theophylline[Text
29 Word] OR magnesium[Text Word] OR thrombolytic[Text Word] OR corticosteroids[Text Word] OR
30 sodium bicarbonate[Text Word] OR erythropoietin[Text Word] OR crystalloid[Text Word] OR
31 colloid[Text Word] OR vitamin c[Text Word] OR ascorbic acid[Text Word] OR vitamin e[Text Word] OR
32 vitamin b[Text Word] OR thiamine[Text Word] OR edavarone[Text Word] OR melatonin[Text Word] OR
33 medical gas[Text Word] OR xenon[Text Word] OR argon[Text Word] OR hydrogen[Text Word] OR
34 hydrogen sulfide[Text Word] OR nitric oxide[Text Word] OR carbon monoxide[Text Word] OR
35 anesthetics[Text Word] OR propofol[Text Word] OR ketamine[Text Word] OR adrenergic alpha
36 agonists[MeSH Terms] OR Adrenergic alpha-1 Receptor Antagonists[MeSH Terms] OR adrenergic beta
37 antagonists[MeSH Terms] OR adjuvants, anesthesia[MeSH Terms] OR analgesics[MeSH Terms] OR
38 anesthetics, dissociative[MeSH Terms] OR anesthetics, local[MeSH Terms] OR anti arrhythmia
39 agents[MeSH Terms] OR antihypertensive agents[MeSH Terms] OR antioxidants[MeSH Terms] OR
40 bronchodilator agents[MeSH Terms] OR cardiotoxic agents[MeSH Terms] OR cardiovascular
41 agents[MeSH Terms] OR cytochrome p 450 CYP1A2 inhibitors[MeSH Terms] OR cytochrome p 450
42 CYP2C9 inhibitors[MeSH Terms] OR cytochrome p 450 CYP2D6 inhibitors[MeSH Terms] OR cytochrome p
43 450 CYP3A inhibitors[MeSH Terms] OR enzyme inhibitors[MeSH Terms] OR excitatory amino acid
44 antagonists[MeSH Terms] OR fibrinolytic agents[MeSH Terms] OR muscarinic antagonists[MeSH Terms]
45 OR mydriatics[MeSH Terms] OR parasympatholytics[MeSH Terms] OR phosphodiesterase 3
46 inhibitors[MeSH Terms] OR potassium channel blockers[MeSH Terms] OR purinergic p1 receptor
47
48
49
50
51
52
53
54
55
56
57
58
59

1
2
3 antagonists[MeSH Terms] OR sympathomimetics[MeSH Terms] OR sympatholytics[MeSH Terms] OR
4 vasoconstrictor agents[MeSH Terms] OR vasodilator agents[MeSH Terms] OR vitamins[MeSH Terms] OR
5 Adrenergic alpha-Agonists[Text Word] OR Adrenergic alpha-1 Receptor Antagonists[Text Word] OR
6 Adrenergic beta-Antagonists[Text Word] OR Adjuvants, Anesthesia[Text Word] OR Analgesics[Text
7 Word] OR Anesthetics, Dissociative[Text Word] OR Anesthetics, Local[Text Word] OR Anti-Arrhythmia
8 Agents[Text Word] OR Antihypertensive Agents[Text Word] OR Antioxidants[Text Word] OR
9 Bronchodilator Agents[Text Word] OR Cardiotonic Agents[Text Word] OR Cardiovascular Agents[Text
10 Word] OR Cytochrome P-450 CYP1A2 Inhibitors[Text Word] OR Cytochrome P-450 CYP2C9
11 Inhibitors[Text Word] OR Cytochrome P-450 CYP2D6 Inhibitors[Text Word] OR Cytochrome P-450 CYP3A
12 Inhibitors[Text Word] OR Enzyme Inhibitors[Text Word] OR Excitatory Amino Acid Antagonists[Text
13 Word] OR Fibrinolytic Agents[Text Word] OR Muscarinic Antagonists[Text Word] OR Mydriatics[Text
14 Word] OR Parasympatholytics[Text Word] OR Phosphodiesterase 3 Inhibitors[Text Word] OR Potassium
15 Channel Blockers[Text Word] OR Purinergic P1 Receptor Antagonists[Text Word] OR
16 Sympathomimetics[Text Word] OR Sympatholytics[Text Word] OR Vasoconstrictor agents[Text Word]
17 OR Vasodilator **2015:2021[mdat]**

18
19
20
21
22 Results 4: 2, 723, 077

23
24 Combined Results 1+2+3+4: 4308

25
26 Date: December 7, 2020
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item
ADMINISTRATIVE INFORMATION		
Title:		
Identification	1a	Identify the report as a protocol of a systematic review
Update	1b	If the protocol is for an update of a previous systematic review, identify as such
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number
Authors:		
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments
Support:		
Sources	5a	Indicate sources of financial or other support for the review
Sponsor	5b	Provide name for the review funder and/or sponsor
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol
INTRODUCTION		
Rationale	6	Describe the rationale for the review in the context of what is already known
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)
METHODS		
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated
Study records:		
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review

1			
2			
3	Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)
4			
5	Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators
6			
7	Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications
8			
9	Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale
10			
11	Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis
12			
13	Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised
14		15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ)
15		15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)
16		15d	If quantitative synthesis is not appropriate, describe the type of summary planned
17			
18	Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)
19			
20	Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)
21			

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.

BMJ Open

Review of Novel Therapeutics in Cardiac Arrest (ReNTICA) - Systematic Review Protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-053304.R1
Article Type:	Protocol
Date Submitted by the Author:	29-Nov-2021
Complete List of Authors:	Murphy, Travis; University of Florida, Department of Emergency Medicine Snipes, Garrett; University of Florida College of Medicine Chowdhury, Muhammad Abdul Baker ; University of Florida Health, Emergency Medicine McCall-Wright, Patti; University of Florida Clinical and Translational Science Institute (CTSI) Aleong, Elizabeth; University of Florida Taylor, Noelle; University of Florida Messina, Maiya-Mari; University of Florida Carrazana, Gabriela; University of Florida Maciel, Carolina; University of Florida Health, Neurology and Neurosurgery Becker, Torben; University of Florida Health, Emergency Medicine
Primary Subject Heading:	Intensive care
Secondary Subject Heading:	Cardiovascular medicine, Neurology, Patient-centred medicine
Keywords:	CLINICAL PHARMACOLOGY, Adult intensive & critical care < INTENSIVE & CRITICAL CARE, Neurological injury < NEUROLOGY, THERAPEUTICS, Adult cardiology < CARDIOLOGY, ACCIDENT & EMERGENCY MEDICINE

SCHOLARONE™
Manuscripts

Review of Novel Therapeutics in Cardiac Arrest (ReNTICA) - Systematic Review Protocol

Travis W. Murphy¹, Garrett Snipes^{1,2}, Muhammad Abdul Baker Chowdhury¹, Patti McCall-Wright³, Elizabeth Aleong⁴, Noelle Taylor⁴, Maiya-Mari Messina⁴, Gabriela Carrazana⁴, Carolina B. Maciel⁵, Torben K. Becker¹

1 University of Florida Department of Emergency Medicine

2 University of Florida Department of Internal Medicine

3 University of Florida Clinical Translational Science Institute

4 University of Florida

5 University of Florida Departments of Neurology and Neurosurgery

Corresponding Author:

Travis W Murphy, MD

1801 NW 9th Ave

Miami, FL 33136

Twm51@miami.edu

Word Count: 2109/4000

I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in BMJ Open and any other BMJ products and to exploit all rights, as set out in our [licence](#).

Travis W Murphy, MD

Abstract

Introduction

Cardiac arrest remains a common and devastating cause of death and disability worldwide. While targeted temperature management has become standard of care to improve functional neurologic outcome, few pharmacologic interventions have shown similar promise.

Methods/analysis

This systematic review will focus on prospective human studies from 2015 to 2020 available in PubMed, Web of Science and EMBASE with a primary focus on impact on functional neurologic outcome. Prospective studies that include pharmacologic agents given during or after cardiac arrest will be included. Study selection will be in keeping with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. If sufficient data involving a given agent are available, a meta-analysis will be conducted and compared to current evidence for therapies recommended in international practice guidelines.

Ethics and dissemination

Formal ethical approval will not be required as primary data will not be collected. The results will be disseminated through peer-reviewed publication, conference presentation and lay press.

Prospero registration number: International Prospective Register for Systematic Reviews (PROSPERO) number CRD42021230216

Article Summary

Strengths and limitations of this study

- Systematic review and meta-analysis of prospective trials investigating therapeutic agents in cardiac arrest.
- Inclusion of outcome measurements to quantify the effect of proposed therapeutic interventions on neurologic function after cardiac arrest.
- Limitation in the number of studies investigating a given therapy may diminish observed effects.
- Potential identification of therapies with positive impact on functional outcome following cardiac arrest.

Introduction

Cardiac arrest remains a common and often devastating cause of death and disability worldwide.[1] Outcomes are contingent on the severity of overall hypoxic-ischemic brain injury burden, which comprises primary injury during circulation standstill and ongoing secondary brain injury that occurs in the aftermath of resuscitation. Aside from targeted temperature management, therapeutic options targeting improvement in neurologic outcome are scarce and recent data has cast doubt on even this guideline-recommended therapy.[2,3] International practice guidelines currently recommend epinephrine/adrenaline, amiodarone and lidocaine/lignocaine.[4–6] While there is good evidence for improved survival with these medications, there is little evidence for a positive impact of these medications on functional neurologic outcomes specifically[4,6,7]. Functional neurologic outcome is less commonly the primary focus of cardiac arrest research but arguably a more granular patient-centered variable rather than rate of return of spontaneous circulation or survival. Unlike targeted temperature management, few advances have been made in pharmacologic approaches to improve functionally intact neurologic survival following cardiac arrest.[2,6,8,9] Several novel compounds have been investigated in animal studies, with some notation of effect on neurologic function, though only a small minority have made the transition from animal models into human trials.[8] The review proposed here will focus on identifying the best available data from human studies and report on therapies that may not have been explicitly mentioned in international guidelines to date.

A similar review of the literature was performed in 2015, though this was focused on cataloging the therapies utilized and did not focus on studies that included functional outcome measurements.[9] Another recent systematic review reported the rate of translation from animal models to human trials for therapies targeted at cardiac arrest.[8] Though again, this review did not have a specific focus on functional neurologic outcome. While the review published by Lind et al. identified the large number of experimental therapies targeted at post-cardiac arrest physiology, the authors noted a relative dearth of clinical trials investigating those same therapies in humans.[8] Additionally, the review published in 2021 did not compare the effects of different pharmacologic agents.[8] The review proposed here seeks to compile the best available evidence for pharmacologic interventions that will improve functional neurologic outcomes in humans following cardiac arrest and compare this directly to current practice guidelines.

Objectives

The objective of our study is to systematically review the literature for prospective studies that evaluated the performance of pharmacologic agents used in adult cardiac arrest compared to standard resuscitation treatments currently advocated in practice guidelines. This will include studies regardless of initial cardiac rhythm and independent of the use of targeted temperature management.

Methods and Design

Population

The systematic review will focus on studies that include patients aged >15 years who have been resuscitated from cardiac arrest but are not conscious upon return of spontaneous circulation with arms for both intervention and control.

Interventions

1
2
3 The interventions to be evaluated include any pharmacologic agent given during cardiac arrest itself or
4 in the immediate post-arrest period (defined as the initial 24 hours).
5

6 **Comparisons**

7 The added benefit of the interventions identified will be compared to current international practice
8 guidelines and the pharmacologic agents advocated there (epinephrine/adrenaline, amiodarone, and
9 lidocaine/lignocaine).
10

11 **Outcome**

12 The primary outcomes required of included studies will be survival and neurologic function as defined by
13 one of the following neurologic scales: Cerebral Performance Category, modified Rankin Scale, Glasgow
14 Outcome Scale/Glasgow Outcome Scale-Extended.
15

16 **Study Design**

17 The systematic review and meta-analysis will include prospective therapeutic studies investigating the
18 use of a pharmacologic agent during or after cardiac arrest with a primary focus on effects on neurologic
19 outcome. This will include systematic reviews, meta-analyses, randomized control trials, adaptive clinical
20 trials, prospective cohort and observational studies, and non-randomized clinical trials. Studies that
21 compare one intervention to standard resuscitation as the control will be included. No minimum
22 number of included subjects will be required. The review will exclude studies without a control group
23 using either placebo or current standard care. Retrospective studies will be excluded including
24 retrospective cohorts, case control studies, cross sectional studies, case reports, and case series. This
25 review has been registered on the International Prospective Register for Systematic Reviews
26 (PROSPERO) number CRD42021230216.
27
28
29
30

31 **Search Strategy**

32 A three-step process will be used to identify eligible studies, including an initial search, title and abstract
33 screening and full-text manuscript review. A professional systematic review librarian (PMW) will develop
34 search criteria in discussion with the authors to include all relevant studies pertaining to adult, human
35 studies of pharmacologic treatment of cardiac arrest. The databases that will be searched are PubMed,
36 Web of Science and EMBASE from the year 2015 to 2020, inclusive. No language restrictions will be
37 applied. Figure 1 shows an example search algorithm for PubMed. Initial deduplication will be
38 performed using EndNote (Clarivate Analytics, Philadelphia, Pennsylvania, USA).[10]
39
40

41 **Study Selection**

42 Literature search results will be uploaded from EndNote and screened through DistillerSR (Evidence
43 Partners, Ottawa, Ontario, Canada). Study titles and abstracts will be screened for relevance in
44 duplicate, blindly and independently, by four reviewers (EA, NT, GC, MM) and adjudicated by a senior
45 author (TM, CM). Eligible studies will then be assessed again for inclusion and for quality in secondary
46 screening through review of full-text manuscripts before data abstraction. This process will be reported
47 using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.
48 The PRISMA-P Checklist pertaining to this protocol is available as Supplement 1. Any conflicting remarks
49 regarding studies will be adjudicated through discussion before inclusion in the final analysis.
50
51

52 **Quality Assessment**

53 Each article will undergo initial screening in parallel by two independent reviewers to minimize bias. All
54 selected articles will be reviewed with senior authors during full-text review. Cochrane tools for
55 assessment of study quality will be utilized as appropriate. (ROBINS-1 and RoB 2.0). Two independent
56
57
58
59
60

1
2
3 authors will assess the risks of bias in studies considered for full-text review in order to determine
4 feasibility of a meta-analysis. Conflicts will be adjudicated with discussion and involvement of a third
5 author (TM or CM) as necessary.
6

7 **Data Extraction**

8 Quantitative data will be extracted from studies meeting inclusion upon full-text review by a
9 professional biostatistician (MABC). Data extracted will be specifically those pertinent to the systematic
10 review and all others that fit into the synthesis of outcome parameters from all studies and meets the
11 potential for inclusion in a meta-analysis. This will include demographics, characteristics of cardiac
12 arrest, medications administered, and outcome parameters as well as any data that are available across
13 all included studies. Data extraction will be independently cross-checked by a senior author and
14 discrepancies resolved through discussion with other senior authors. Data produced from this
15 systematic review including the statistical code and dataset of articles screened will be published in a
16 data repository.
17
18

19 **Endpoint**

20 Results of the systematic review will be grouped by drug and drug class. The primary outcomes will be
21 survival and neurologic function as defined by one of the following performance scales: Cerebral
22 Performance Category, modified Rankin Scale, Glasgow Outcome Scale/Glasgow Outcome Scale-
23 Extended. Provided they are available in the original studies, secondary outcomes will be ICU length of
24 stay, Ventilator days, rates of sepsis, rates of pneumonia, rate of tracheostomy, rate of acute kidney
25 injury and need for CVVH/HD (in the hospital or afterwards). We will also include secondary outcomes of
26 functional capacity including Barthel Index, Katz Index, Lawton-Brody Instrumental Activities of Daily
27 Living Scale, and rates of discharge to rehab facility if included in the original studies. Any follow-up
28 duration will be accepted as there is considerable variability in the existing literature.
29
30
31

32 **Patient and Public Involvement**

33 No patients were involved with the planning of this protocol.
34
35

36 **Analysis**

37 **Descriptive Analysis**

38 A narrative synthesis of the final studies included will be developed based on the different
39 pharmacologic agents identified. The impact of each of these agents on the primary and secondary
40 outcome mentioned above will be described in addition to a formal meta-analysis of studies using each
41 pharmacologic agent identified.
42
43
44

45 **Statistical Analysis**

46 The primary focus of this review is to detect evidence for the impact of the pharmacologic agents
47 identified on survival and functional neurologic outcome. As functional outcome is reported with some
48 degree of heterogeneity, we are including three of the most widely reported functional outcome scales
49 and not limiting to one over the others. As functional neurologic outcome is not always explicitly
50 reported using one of these sales, we do anticipate some limitation in the ability to directly compare
51 one agent to another. However, when available, pharmacologic agents will be compared as equitably as
52 possible using all available outcome parameters reported in the index studies. The percentage of
53 patients receiving a given pharmacologic agent with a favorable neurologic outcome according to each
54 specific scale will be reported. Based on the availability of data from primary sources, subgroup analysis
55
56
57
58
59
60

1
2
3 within cohorts treated with the same pharmacologic agent will also be performed to identify
4 populations most likely to benefit from a given agent.
5

6 **Data synthesis**

7 Results will be presented in accordance with the Preferred Reporting Items for Systematic Reviews and
8 Meta-Analysis (PRISMA) statement. A PRISMA flow diagram will be used to summarize study selection.
9 Tabulated data showing relative proportion of patients with favorable functional neurologic outcome for
10 each pharmacologic agent will be presented. We will rank agents by proportion of favorable outcomes.
11 For secondary outcome variables, we will present synthesized data as available in separate tables but
12 will otherwise provide a separate narrative summary of the data available for each agent. We will
13 produce a hierarchy of pharmacologic agents based on the quality of evidence available and degree of
14 effects on outcome variables.
15
16

17 **Meta-analysis**

18 A meta-analysis of the pharmacologic agents found to have been studied with a focus on functional
19 neurologic outcome will be performed. The results of this meta-analysis will then be compared to the
20 best available evidence for medications recommended in practice guidelines to provide context and
21 rank relative efficacy.
22
23

24 **Discussion**

25
26 This systematic review and meta-analysis will provide evidence for further study or use of compounds
27 that are most likely to benefit patients following cardiac arrest in terms of functional status. The
28 conclusions will be the result of careful accumulation of the highest-quality evidence available and will
29 compare to current practice guidelines to place the effects in context. With a primary focus on the
30 ability of a given pharmacologic agent to not only provide a survival benefit but protect the neurologic
31 function of patients following cardiac arrest, this review and meta-analysis will be unique in its aim to
32 identify agents with the greatest potential to benefit these patients.
33
34

35 **Ethics and dissemination**

36
37 No ethical or safety considerations were considered based on the nature of this review. Dissemination
38 of findings through a peer-reviewed publication upon the conclusion of the meta-analysis.
39
40

41 **Author Contributions**

42
43 *Travis Murphy*: Conception and design of work, analysis, drafting of work, final approval *Garrett Snipes*:
44 Conception and design of work, drafting of work *Muhammad Abdul Baker Chowdhury*: Conception and
45 design of work, analysis *Patti McCall-Wright*: Conception and design of work, analysis *Elizabeth Aleong*:
46 Analysis *Noelle Taylor*: Analysis *Maiya Messina*: Analysis *Gabriela Carrazana*: Analysis *Carolina Maciel*:
47 Conception and design of work, analysis *Torben Becker*: Conception and design of work. All authors have
48 reviewed and contributed to this final written manuscript.
49
50

51 **Funding statement**

52
53 This project received funding from the University of Florida Center for Translational Science Institute
54 (Voucher #LSR06-001) to support professional library services.
55
56
57
58
59
60

Competing interests statement

The authors have no competing interests.

References

- [1] Kiguchi T, Okubo M, Nishiyama C, Maconochie I, Ong MEH, Kern KB, et al. Out-of-hospital cardiac arrest across the World: First report from the International Liaison Committee on Resuscitation (ILCOR). *Resuscitation* 2020;152:39–49. <https://doi.org/10.1016/j.resuscitation.2020.02.044>.
- [2] Panchal AR, Berg KM, Hirsch KG, Kudenchuk PJ, Del Rios M, Cabanãs JG, et al. 2019 American Heart Association Focused Update on Advanced Cardiovascular Life Support: Use of Advanced Airways, Vasopressors, and Extracorporeal Cardiopulmonary Resuscitation during Cardiac Arrest: An Update to the American Heart Association Guidelines f. *Circulation* 2019;140:E881–94. <https://doi.org/10.1161/CIR.0000000000000732>.
- [3] Dankiewicz J, Cronberg T, Lilja G, Jakobsen JC, Levin H, Ullén S, et al. Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest. *N Engl J Med* 2021;384:2283–94. https://doi.org/10.1056/NEJMOA2100591/SUPPL_FILE/NEJMOA2100591_DATA-SHARING.PDF.
- [4] Panchal AR, Berg KM, Kudenchuk PJ, Del Rios M, Hirsch KG, Link MS, et al. 2018 American Heart Association Focused Update on Advanced Cardiovascular Life Support Use of Antiarrhythmic Drugs During and Immediately After Cardiac Arrest: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Em. *Circulation* 2018;138:e740–9. <https://doi.org/10.1161/CIR.0000000000000613>.
- [5] Holmberg MJ, Issa MS, Moskowitz A, Morley P, Welsford M, Neumar RW, et al. Vasopressors during adult cardiac arrest: A systematic review and meta-analysis. *Resuscitation* 2019. <https://doi.org/10.1016/j.resuscitation.2019.04.008>.
- [6] Soar J, MacOnochie I, Wyckoff MH, Olasveengen TM, Singletary EM, Greif R, et al. 2019 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations: Summary from the Basic Life Support; Advanced Life Support; Pediatric Life Support; Neonatal Life Support; Education, I. *Circulation* 2019. <https://doi.org/10.1161/CIR.0000000000000734>.
- [7] Kudenchuk PJ, Brown SP, Daya M, Rea T, Nichol G, Morrison LJ, et al. Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest. *N Engl J Med* 2016;374:1711–22. <https://doi.org/10.1056/nejmoa1514204>.
- [8] Lind PC, Johannsen CM, Vammen L, Magnussen A, Andersen LW, Granfeldt A. Translation from animal studies of novel pharmacological therapies to clinical trials in cardiac arrest: A systematic review. *Resuscitation* 2021;158:258–69. <https://doi.org/10.1016/j.resuscitation.2020.10.028>.
- [9] Lundin A, Djärv T, Engdahl J, Hollenberg J, Nordberg P, Ravn-Fischer A, et al. Drug therapy in cardiac arrest: A review of the literature. *Eur Hear J - Cardiovasc Pharmacother* 2016;2:54–75. <https://doi.org/10.1093/ehjcvp/pvv047>.
- [10] Bramer WM, Giustini D, De Jonge GB, Holland L, Bekhuis T. De-duplication of database search results for systematic reviews in EndNote. *J Med Libr Assoc* 2016;104:240–3. <https://doi.org/10.5195/jmla.2016.24>.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16 **Figure 1. Example Search Algorithm for PubMed**

17 **PubMed**

18
19
20 **Cardiac Arrest**

21
22 cardiac arrest[MeSH Terms] OR arrest, cardiopulmonary[MeSH Terms] OR heart arrest[MeSH Terms] OR
23 deep hypothermic circulatory arrest[MeSH Terms] OR ventricular fibrillation[MeSH Terms] OR
24 ventricular tachycardia[MeSH Terms] OR asystole[MeSH Terms] OR cardiopulmonary
25 resuscitation[MeSH Terms] OR advanced cardiac life support[MeSH Terms] OR cardiac death[MeSH
26 Terms] OR sudden cardiac death[MeSH Terms] OR cardiac death, sudden[MeSH Terms] OR cardiac
27 arrest[Text Word] OR cardiopulmonary arrest[Text Word] OR heart arrest[Text Word] OR circulatory
28 arrest[Text Word] OR ventricular fibrillation[Text Word] OR ventricular tachycardia[Text Word] OR
29 pulseless electrical activity[Text Word] OR asystole[Text Word] OR cardiovascular arrest[Text Word] OR
30 cardiopulmonary arrest[Text Word] OR cardiopulmonary resuscitation[Text Word] OR defibrillation[Text
31 Word] OR advanced cardiac life support[Text Word] OR ACLS[Text Word] OR cardiac death[Text Word]
32 OR sudden cardiac death[Text Word] OR fatal arrhythmia[Text Word] **2015:2021[pdat]**

33
34
35
36
37
38 Results 1: 57,400

39 **AND**

40
41 **Survival**

42
43 survival[MeSH Terms] OR mortality[MeSH Terms] OR survival[Text Word] OR mortality[Text Word]
44 **2015:2021[pdat]**

45
46 Results 2: 705, 713

47
48 **AND**

49
50 **Functional Outcome**

51
52 glasgow outcome scale[MeSH Terms] OR glasgow outcome scale[Text Word] OR modified rankin
53 scale[Text Word] OR cerebral performance categories score[Text Word] OR prognosis[MeSH Terms] OR
54 disability evaluation[MeSH Terms] OR prognosis[Text Word] OR disability evaluation[Text Word]
55 **2015:2021[pdat]**

1
2
3 Results 3: 603,078
4

5 **AND**

6
7 **Pharmacology**

8 drug*[Text Word] OR drug therapy[Text Word] OR medication[Text Word] OR phamacolog*[Text Word]
9 OR pharmaceutical*[Text Word] OR therap*[Text Word] OR injection[Text Word] OR infusion[Text Word]
10 OR cardiovascular agents[Text Word] OR drug administration schedule[Text Word] OR therapeutics[Text
11 Word] OR intravenous administration[Text Word] OR dose response relationship[Text Word] OR
12 cardiovascular agents[MeSH Terms] OR therapeutics[MeSH Terms] OR drug administration
13 schedule[MeSH Terms] OR dose response relationship, drug[MeSH Terms] OR vasopressor agents[MeSH
14 Terms] OR epinephrine[MeSH Terms] OR vasopressins[MeSH Terms] OR norepinephrine[MeSH Terms]
15 OR Simendan[MeSH Terms] OR methoxamine[MeSH Terms] OR amiodarone[MeSH Terms] OR sodium
16 channel blockers[MeSH Terms] OR lidocaine[MeSH Terms] OR lignocaine[MeSH Terms] OR
17 procainamide[MeSH Terms] OR flecainide[MeSH Terms] OR mexiletine[MeSH Terms] OR
18 quinidine[MeSH Terms] OR adrenergic beta blockers[MeSH Terms] OR sotalol[MeSH Terms] OR apo
19 labetalol[MeSH Terms] OR metoprolol[MeSH Terms] OR nadolol[MeSH Terms] OR bisoprolol[MeSH
20 Terms] OR carvedilol[MeSH Terms] OR isoproterenol[MeSH Terms] OR calcium channel blockers[MeSH
21 Terms] OR diltiazem[MeSH Terms] OR verapamil[MeSH Terms] OR digoxin[MeSH Terms] OR
22 isoprenaline[MeSH Terms] OR theophylline[MeSH Terms] OR aminophylline[MeSH Terms] OR
23 magnesium[MeSH Terms] OR thrombolytic agents[MeSH Terms] OR thrombolytic drugs[MeSH Terms]
24 OR thrombolytic therapies[MeSH Terms] OR corticosteroids[MeSH Terms] OR sodium
25 bicarbonate[MeSH Terms] OR erythropoietin[MeSH Terms] OR crystalloid solutions[MeSH Terms] OR
26 ascorbic acid[MeSH Terms] OR vitamin e[MeSH Terms] OR vitamin b1[MeSH Terms] OR
27 melatonin[MeSH Terms] OR colloids[MeSH Terms] OR xenon[MeSH Terms] OR argon[MeSH Terms] OR
28 hydrogen[MeSH Terms] OR hydrogen sulfide[MeSH Terms] OR nitric oxide[MeSH Terms] OR carbon
29 monoxide[MeSH Terms] OR anesthetic agents[MeSH Terms] OR anesthetic drugs[MeSH Terms] OR
30 propofol[MeSH Terms] OR ketamine[MeSH Terms] OR vasopressor[Text Word] OR epinephrine[Text
31 Word] OR vasopressin[Text Word] OR norepinephrine[Text Word] OR levosimendan[Text Word] OR
32 simendan[Text Word] OR methoxamine[Text Word] OR amiodarone[Text Word] OR sodium channel
33 blockers[Text Word] OR lidocaine[Text Word] OR lignocaine[Text Word] OR procainamide[Text Word]
34 OR flecainide[Text Word] OR mexiletine[Text Word] OR quinidine[Text Word] OR beta blocker[Text
35 Word] OR sotalol[Text Word] OR labetalol[Text Word] OR metoprolol[Text Word] OR nadolol[Text
36 Word] OR bisoprolol[Text Word] OR carvedilol[Text Word] OR isoproterenol[Text Word] OR calcium
37 channel blocker[Text Word] OR diltiazem[Text Word] OR verapamil[Text Word] OR atropine[Text Word]
38 OR atropine[MeSH Terms] OR digoxin[Text Word] OR isoprenaline[Text Word] OR theopylline[Text
39 Word] OR magnesium[Text Word] OR thrombolytic[Text Word] OR corticosteroids[Text Word] OR
40 sodium bicarbonate[Text Word] OR erythropoietin[Text Word] OR crystalloid[Text Word] OR
41 colloid[Text Word] OR vitamin c[Text Word] OR ascorbic acid[Text Word] OR vitamin e[Text Word] OR
42 vitamin b[Text Word] OR thiamine[Text Word] OR edavarone[Text Word] OR melatonin[Text Word] OR
43 medical gas[Text Word] OR xenon[Text Word] OR argon[Text Word] OR hydrogen[Text Word] OR
44 hydrogen sulfide[Text Word] OR nitric oxide[Text Word] OR carbon monoxide[Text Word] OR
45 anesthetics[Text Word] OR propofol[Text Word] OR ketamine[Text Word] OR adrenergic alpha
46 agonists[MeSH Terms] OR Adrenergic alpha-1 Receptor Antagonists[MeSH Terms] OR adrenergic beta
47 antagonists[MeSH Terms] OR adjuvants, anesthesia[MeSH Terms] OR analgesics[MeSH Terms] OR
48
49
50
51
52
53
54
55
56
57
58
59

1
2
3 anesthetics, dissociative[MeSH Terms] OR anesthetics, local[MeSH Terms] OR anti arrhythmia
4 agents[MeSH Terms] OR antihypertensive agents[MeSH Terms] OR antioxidants[MeSH Terms] OR
5 bronchodilator agents[MeSH Terms] OR cardiotoxic agents[MeSH Terms] OR cardiovascular
6 agents[MeSH Terms] OR cytochrome p 450 CYP1A2 inhibitors[MeSH Terms] OR cytochrome p 450
7 CYP2C9 inhibitors[MeSH Terms] OR cytochrome p 450 CYP2D6 inhibitors[MeSH Terms] OR cytochrome p
8 450 CYP3A inhibitors[MeSH Terms] OR enzyme inhibitors[MeSH Terms] OR excitatory amino acid
9 antagonists[MeSH Terms] OR fibrinolytic agents[MeSH Terms] OR muscarinic antagonists[MeSH Terms]
10 OR mydriatics[MeSH Terms] OR parasympatholytics[MeSH Terms] OR phosphodiesterase 3
11 inhibitors[MeSH Terms] OR potassium channel blockers[MeSH Terms] OR purinergic p1 receptor
12 antagonists[MeSH Terms] OR sympathomimetics[MeSH Terms] OR sympatholytics[MeSH Terms] OR
13 vasoconstrictor agents[MeSH Terms] OR vasodilator agents[MeSH Terms] OR vitamins[MeSH Terms] OR
14 Adrenergic alpha-Agonists[Text Word] OR Adrenergic alpha-1 Receptor Antagonists[Text Word] OR
15 Adrenergic beta-Antagonists[Text Word] OR Adjuvants, Anesthesia[Text Word] OR Analgesics[Text
16 Word] OR Anesthetics, Dissociative[Text Word] OR Anesthetics, Local[Text Word] OR Anti-Arrhythmia
17 Agents[Text Word] OR Antihypertensive Agents[Text Word] OR Antioxidants[Text Word] OR
18 Bronchodilator Agents[Text Word] OR Cardiotoxic Agents[Text Word] OR Cardiovascular Agents[Text
19 Word] OR Cytochrome P-450 CYP1A2 Inhibitors[Text Word] OR Cytochrome P-450 CYP2C9
20 Inhibitors[Text Word] OR Cytochrome P-450 CYP2D6 Inhibitors[Text Word] OR Cytochrome P-450 CYP3A
21 Inhibitors[Text Word] OR Enzyme Inhibitors[Text Word] OR Excitatory Amino Acid Antagonists[Text
22 Word] OR Fibrinolytic Agents[Text Word] OR Muscarinic Antagonists[Text Word] OR Mydriatics[Text
23 Word] OR Parasympatholytics[Text Word] OR Phosphodiesterase 3 Inhibitors[Text Word] OR Potassium
24 Channel Blockers[Text Word] OR Purinergic P1 Receptor Antagonists[Text Word] OR
25 Sympathomimetics[Text Word] OR Sympatholytics[Text Word] OR Vasoconstrictor agents[Text Word]
26 OR Vasodilator **2015:2021[pdat]**

32 Results 4: 2, 723, 077

33 Combined Results 1+2+3+4: 4308

34 Date: December 7, 2020

Figure 1. Example Search Algorithm for PubMed**Cardiac Arrest**

cardiac arrest[MeSH Terms] OR arrest, cardiopulmonary[MeSH Terms] OR heart arrest[MeSH Terms] OR deep hypothermic circulatory arrest[MeSH Terms] OR ventricular fibrillation[MeSH Terms] OR ventricular tachycardia[MeSH Terms] OR asystole[MeSH Terms] OR cardiopulmonary resuscitation[MeSH Terms] OR advanced cardiac life support[MeSH Terms] OR cardiac death[MeSH Terms] OR sudden cardiac death[MeSH Terms] OR cardiac death, sudden[MeSH Terms] OR cardiac arrest[Text Word] OR cardiopulmonary arrest[Text Word] OR heart arrest[Text Word] OR circulatory arrest[Text Word] OR ventricular fibrillation[Text Word] OR ventricular tachycardia[Text Word] OR pulseless electrical activity[Text Word] OR asystole[Text Word] OR cardiovascular arrest[Text Word] OR cardiopulmonary arrest[Text Word] OR cardiopulmonary resuscitation[Text Word] OR defibrillation[Text Word] OR advanced cardiac life support[Text Word] OR ACLS[Text Word] OR cardiac death[Text Word] OR sudden cardiac death[Text Word] OR fatal arrhythmia[Text Word] **2015:2021[mdat]**

Results 1: 57,400

AND**Survival**

survival[MeSH Terms] OR mortality[MeSH Terms] OR survival[Text Word] OR mortality[Text Word] **2015:2021[mdat]**

Results 2: 705, 713

AND**Functional Outcome**

glasgow outcome scale[MeSH Terms] OR glasgow outcome scale[Text Word] OR modified rankin scale[Text Word] OR cerebral performance categories score[Text Word] OR prognosis[MeSH Terms] OR disability evaluation[MeSH Terms] OR prognosis[Text Word] OR disability evaluation[Text Word] **2015:2021[mdat]**

Results 3: 603,078

AND**Pharmacology**

drug*[Text Word] OR drug therapy[Text Word] OR medication[Text Word] OR pharmacolog*[Text Word] OR pharmaceutical*[Text Word] OR therap*[Text Word] OR injection[Text Word] OR infusion[Text Word] OR cardiovascular agents[Text Word] OR drug administration schedule[Text Word] OR therapeutics[Text Word] OR in travenous administration[Text Word] OR dose response relationship[Text Word] OR cardiovascular agents[MeSH Terms] OR therapeutics[MeSH Terms] OR drug administration schedule[MeSH Terms] OR dose response relationship, drug[MeSH Terms] OR vasopressor agents[MeSH Terms] OR epinephrine[MeSH Terms] OR vasopressins[MeSH Terms] OR norepinephrine[MeSH Terms] OR Simendan[MeSH Terms] OR methoxamine[MeSH Terms] OR amidarone[MeSH Terms] OR sodium channel blockers[MeSH Terms] OR lidocaine[MeSH Terms] OR lignocaine[MeSH Terms] OR procainamide[MeSH Terms] OR flecainide[MeSH Terms] OR mexiletine[MeSH Terms] OR quinidine[MeSH Terms] OR adrenergic beta blockers[MeSH Terms] OR sotalol[MeSH Terms] OR apo labetalol[MeSH Terms] OR metoprolol[MeSH Terms] OR nadolol[MeSH Terms] OR bisoprolol[MeSH Terms] OR carvedilol[MeSH Terms] OR isoproterenol[MeSH Terms] OR calcium channel blockers[MeSH Terms] OR diltiazem[MeSH Terms] OR verapamil[MeSH Terms] OR digoxin[MeSH Terms] OR isoprenaline[MeSH Terms] OR theophylline[MeSH Terms] OR aminophylline[MeSH Terms] OR magnesium[MeSH Terms] OR thrombolytic agents[MeSH Terms] OR thrombolytic drugs[MeSH Terms] OR thrombolytic therapies[MeSH Terms] OR corticosteroids[MeSH Terms] OR sodium bicarbonate[MeSH Terms] OR erythropoietin[MeSH Terms] OR crystalloid solutions[MeSH Terms] OR ascorbic acid[MeSH Terms] OR vitamin e[MeSH Terms] OR vitamin b1[MeSH Terms] OR melatonin[MeSH Terms] OR colloids[MeSH Terms] OR xenon[MeSH Terms] OR argon[MeSH Terms] OR hydrogen[MeSH Terms] OR hydrogen sulfide[MeSH Terms] OR nitric oxide[MeSH Terms] OR carbon monoxide[MeSH Terms] OR anesthetic agents[MeSH Terms] OR anesthetic drugs[MeSH Terms] OR propofol[MeSH Terms] OR ketamine[MeSH Terms] OR vasopressor[Text Word] OR epinephrine[Text Word] OR vasopressin[Text Word] OR norepinephrine[Text Word] OR levosimendan[Text Word] OR simendan[Text Word] OR methoxamine[Text Word] OR amidarone[Text Word] OR sodium channel blockers[Text Word] OR lidocaine[Text Word] OR lignocaine[Text Word] OR procainamide[Text Word] OR flecainide[Text Word] OR mexiletine[Text Word] OR quinidine[Text Word] OR beta blocker[Text Word] OR sotalol[Text Word] OR labetalol[Text Word] OR metoprolol[Text Word] OR nadolol[Text Word] OR bisoprolol[Text Word] OR carvedilol[Text Word] OR isoproterenol[Text Word] OR calcium channel blocker[Text Word] OR diltiazem[Text Word] OR verapamil[Text Word] OR atropine[Text Word] OR atropine[MeSH Terms] OR digoxin[Text Word] OR isoprenaline[Text Word] OR theophylline[Text Word] OR magnesium[Text Word] OR thrombolytic[Text Word] OR corticosteroids[Text Word] OR sodium bicarbonate[Text Word] OR erythropoietin[Text Word] OR crystalloid[Text Word] OR colloid[Text Word] OR vitamin c[Text Word] OR ascorbic acid[Text Word] OR vitamin e[Text Word] OR vitamin b[Text Word] OR thiamine[Text Word] OR edavarone[Text Word] OR melatonin[Text Word] OR medical gas[Text Word] OR xenon[Text Word] OR argon[Text Word] OR hydrogen[Text Word] OR hydrogen sulfide[Text Word] OR nitric oxide[Text Word] OR carbon monoxide[Text Word] OR anesthetics[Text Word] OR propofol[Text Word] OR ketamine[Text Word] OR adrenergic alpha agonists[MeSH Terms] OR Adrenergic alpha-1 Receptor Antagonists[MeSH Terms] OR adrenergic beta antagonists[MeSH Terms] OR adjuvants, anesthesia[MeSH Terms] OR analgesics[MeSH Terms] OR anesthetics, dissociative[MeSH Terms] OR anesthetics, local[MeSH Terms] OR anti arrhythmia agents[MeSH Terms] OR antihypertensive agents[MeSH Terms] OR antioxidants[MeSH Terms] OR bronchodilator agents[MeSH Terms] OR cardiotoxic agents[MeSH Terms] OR cardiovascular agents[MeSH Terms] OR cytochrome p 450 CYP1A2 inhibitors[MeSH Terms] OR cytochrome p 450 CYP2C9 inhibitors[MeSH Terms] OR cytochrome p 450 CYP2D6 inhibitors[MeSH Terms] OR cytochrome p 450 CYP3A inhibitors[MeSH Terms] OR enzyme inhibitors[MeSH Terms] OR excitatory amino acid antagonists[MeSH Terms] OR fibrinolytic agents[MeSH Terms] OR muscarinic antagonists[MeSH Terms] OR mydriatics[MeSH Terms] OR parasympatholytics[MeSH Terms] OR phosphodiesterase 3 inhibitors[MeSH Terms] OR potassium channel blockers[MeSH Terms] OR purinergic p1 receptor antagonists[MeSH Terms] OR sympathomimetics[MeSH Terms] OR sympatholytics[MeSH Terms] OR vasoconstrictor agents[MeSH Terms] OR vasodilator agents[MeSH Terms] OR vitamins[MeSH Terms] OR Adrenergic alpha-Agonists[Text Word] OR Adrenergic alpha-1 Receptor Antagonists[Text Word] OR Adrenergic beta-Antagonists[Text Word] OR Adjuvants, Anesthesia[Text Word] OR Analgesics[Text Word] OR Anesthetics, Dissociative[Text Word] OR Anesthetics, Local[Text Word] OR Anti-Arrhythmia Agents[Text Word] OR Antihypertensive Agents[Text Word] OR Antioxidants[Text Word] OR Bronchodilator Agents[Text Word] OR Cardiotonic Agents[Text Word] OR Cardiovascular Agents[Text Word] OR Cytochrome P-450 CYP1A2 Inhibitors[Text Word] OR Cytochrome P-450 CYP2C9 Inhibitors[Text Word] OR Cytochrome P-450 CYP2D6 Inhibitors[Text Word] OR Cytochrome P-450 CYP3A Inhibitors[Text Word] OR Enzyme Inhibitors[Text Word] OR Excitatory Amino Acid Antagonists[Text Word] OR Fibrinolytic Agents[Text Word] OR Muscarinic Antagonists[Text Word] OR Mydriatics[Text Word] OR Parasympatholytics[Text Word] OR Phosphodiesterase 3 Inhibitors[Text Word] OR Potassium Channel Blockers[Text Word] OR Purinergic P1 Receptor Antagonists[Text Word] OR Sympathomimetics[Text Word] OR Sympatholytics[Text Word] OR Vasoconstrictor agents[Text Word] OR Vasodilator **2015:2021[mdat]**

Results 4: 2, 723, 077

Combined Results 1+2+3+4: 4308

Date: December 7, 2020

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item	Page Number
ADMINISTRATIVE INFORMATION			
Title:			
Identification	1a	Identify the report as a protocol of a systematic review	1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	n/a
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	2
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	6
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	n/a
Support:			
Sources	5a	Indicate sources of financial or other support for the review	6
Sponsor	5b	Provide name for the review funder and/or sponsor	n/a
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	n/a
INTRODUCTION			
Rationale	6	Describe the rationale for the review in the context of what is already known	3
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	3
METHODS			
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	3-5
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	4
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	Fig. 1

Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	4
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	4
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	4
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	5
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	5
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	4
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	5-6
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ)	6
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	6
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	N/a
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	4

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.